O
REGN icon

Ossiam’s Regeneron Pharmaceuticals REGN Stock Holding History

Ossiam’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.35M Sell
12,103
-2,587
-18% -$1.98M 0.16% 75
2025
Q4 		$11.3M Buy
14,690
+1,666
+13% +$1.13M 0.23% 60
2025
Q3 		$7.32M Sell
13,024
-2,136
-14% -$1.21M 0.09% 151
2025
Q2 		$7.96M Sell
15,160
-22,234
-59% -$12.4M 0.09% 142
2025
Q1 		$23.7M Buy
37,394
+21,221
+131% +$14.6M 0.33% 55
2024
Q4 		$11.5M Sell
16,173
-997
-6% -$837K 0.2% 80
2024
Q3 		$18M Sell
17,170
-752
-4% -$837K 0.35% 59
2024
Q2 		$18.8M Buy
17,922
+12,493
+230% +$12.1M 0.36% 62
2024
Q1 		$5.23M Buy
5,429
+302
+6% +$287K 0.09% 138
2023
Q4 		$4.5M Buy
5,127
+1,322
+35% +$1.09M 0.07% 128
2023
Q3 		$3.13M Sell
3,805
-37,071
-91% -$29.1M 0.06% 154
2023
Q2 		$29.4M Buy
40,876
+37,664
+1,173% +$29M 0.53% 51
2023
Q1 		$2.64M Buy
3,212
+2,312
+257% +$1.74M 0.05% 176
2022
Q4 		$649K Sell
900
-723
-45% -$533K 0.02% 334
2022
Q3 		$1.12M Sell
1,623
-389
-19% -$245K 0.03% 240
2022
Q2 		$1.19M Sell
2,012
-6,528
-76% -$4.24M 0.04% 210
2022
Q1 		$5.96M Buy
8,540
+16
+0.2% +$10.1K 0.16% 94
2021
Q4 		$5.38M Buy
8,524
+620
+8% +$381K 0.14% 120
2021
Q3 		$4.78M Sell
7,904
-2,783
-26% -$1.73M 0.14% 115
2021
Q2 		$6.14M Buy
10,687
+1,774
+20% +$899K 0.17% 93
2021
Q1 		$4.22M Buy
8,913
+8,841
+12,279% +$4.3M 0.13% 113
2020
Q4 		$35K Sell
72
-4,003
-98% -$2.16M ﹤0.01% 395
2020
Q3 		$2.28M Sell
4,075
-2,511
-38% -$1.52M 0.1% 132
2020
Q2 		$4.11M Buy
6,586
+2,335
+55% +$1.33M 0.26% 77
2020
Q1 		$2.08M Buy
4,251
+4,111
+2,936% +$1.7M 0.14% 119
2019
Q4 		$53K Sell
140
-98
-41% -$33K ﹤0.01% 460
2019
Q3 		$66K Buy
238
+173
+266% +$51.2K ﹤0.01% 397
2019
Q2 		$20K Sell
65
-173
-73% -$57.6K ﹤0.01% 456
2019
Q1 		$98K Sell
238
-78
-25% -$32.1K 0.01% 242
2018
Q4 		$118K Buy
+316
New +$116K 0.02% 223

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ossiam's REGN Position: Q1 2026 in Review

Ossiam reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2026, selling an estimated $1.98M and leaving 12,103 shares worth $9.35M. The position accounts for 0.16% of the portfolio, ranked #75.

Ossiam first reported a position in REGN in Q4 2018 and has held it in 30 quarters since. The position peaked at $29.4M in Q2 2023. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Ossiam held 12,103 shares of Regeneron Pharmaceuticals worth $9.35M as of Q1 2026.
  • Ossiam sold 2,587 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.98M.
  • Regeneron Pharmaceuticals made up 0.16% of Ossiam's portfolio in Q1 2026, its #75 holding.
  • Ossiam first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • Ossiam's Regeneron Pharmaceuticals position peaked at $29.4M in Q2 2023.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ossiam's 13F filing for Q1 2026, filed 14 May 2026.